Introduction:
The prevalence of carbapenem resistance in Acinetobacter baumannii has
been increasing worldwide, and therapeutic options are extremely limited. We performed a systematic
review to evaluate the phenotypic and genotypic carbapenem resistance in A.baumannii
reported in Iran.
Methods:
We systematically searched Pub Med, Web of Science Direct, and Google scholar databases
to identify studies addressing the carbapenem resistance of A. baumannii. The selected papers
were published between 2005 and 2016, but the sample collection period was between 2002
and 2016. To estimate the prevalence, the Der Simonian and Laird randomized models, a 95%
confidence interval, was used. For the heterogeneity check, I2 test was used. The Egger test was
used to check the propagation bias.
Results:
Analysis of data indicates that there was an increase in resistance to carbapenems from
4.5% in 2005 to a 100% prevalence rate in 2016 (65.4 (95% CI: 58.8 – 71.6).
Conclusion:
According to the results of this study, the rate of resistance to carbapenem in
A.baumannii has been increasing in Iran. The presence of carbapenem-resistant isolates is a major
concern, because carbapenem is the main drug used against Multi Drug Resistant (MDR) isolates.
Clinical efficacy and safety of polymyxins based versus non-polymyxins based therapies in the infections caused by carbapenem-resistant Acinetobacter baumannii: a systematic review and meta-analysis
